National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
NCCN ORP Recent News
NCCN ORP Affiliate Research Project
NCCN ORP Scientific Publications
NCCN ORP for Industry
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN Informed Consent Language Database
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

NCCN ORP Grant History

The NCCN ORP has received millions of dollars in research grants from major pharmaceutical companies to support investigator-initiated trials, which explore new venues of clinical investigation that answer important scientific questions. Studies evaluate innovative combinations and sequencing regimens of drugs, mechanisms of action of specific agents, or drug resistance or are directed toward exploring extended uses for specific agents.

NCCN has received the following grants to support investigator-initiated trials:

  • Abraxis BioScience, Inc. and AstraZeneca – $2,075,000 for clinical studies of nab-paclitaxel
  • Allos Therapeutics, Inc. – $2,300,000 for clinical studies of pralatrexate
  • AVEO Pharmaceuticals, Inc. and Astellas Pharmaceuticals, Inc. – $2,000,000 for clinical studies of tivozanib
  • Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. – $1,200,000 for clinical studies of sorafenib
  • Boehringer Ingelheim, Pharmaceuticals, Inc. – $2,000,000 for clinical studies of afatinib
  • Bristol-Myers Squibb Company and ImClone Systems Incorporated – $3,445,231 for clinical studies of cetuximab in head and neck cancers and bladder cancers
  • Cephalon, Inc. – $1,391,193 for clinical studies of bendamustine
  • GlaxoSmithKline LLC – $2,000,000 for pre-clinical and clinical studies of dabrafenib
  • GlaxoSmithKline LLC – $2,000,000 for clinical studies of pazopanib
  • GlaxoSmithKline LLC – $2,000,000 for clinical studies of ofatumumab
  • GlaxoSmithKline LLC – $2,000,000 for clinical studies of trametinib
  • Merck & Co., Inc. – $1,046,380 for clinical studies of vorinostat
  • Pfizer, Inc. – $3,150,000 for clinical studies of irinotecan and celecoxib
  • Pfizer, Inc. – $2,000,000 for preclinical and specialized imaging studies of sunitinib
  • Pfizer, Inc. – $2,100,000 for clinical studies of axitinib
  • Roche Laboratories, Inc. – $2,500,000 for clinical studies of capecitabine
  • Wyeth – $4,150,000 for clinical studies of temsirolimus

 

Afatinib Studies
Axitinib Studies
Bendamustine Studies
Capecitabine Studies
Celecoxib Studies
Cetuximab Studies
Dabrafenib Studies
Irinotecan Studies
nab-Paclitaxel Studies
Ofatumumab Studies
Pazopanib Studies
Pralatrexate Studies
Sorafenib Studies
Sunitinib Studies (Preclinical)
Sunitinib Studies (Specialized Imaging)
Temsirolimus Studies
Tivozanib Studies
Trametinib Studies
Vorinostat Studies

 

Afatinib Studies

INVESTIGATOR

MEMBER INSTITUTION

STUDY
Matthew Fury, MD, PhD Memorial Sloan-Kettering Cancer Center Phase I Study of Induction Chemotherapy with Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
Jamie Chaft, MD Memorial Sloan-Kettering Cancer Center A Dose-Finding Study of Afatinib in Combination with Cisplatin or Carboplatin + Pemetrexed in Patients with EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Danielle Margalit, MD, MPH Dana-Farber/Brigham and Women’s  Cancer Center Phase I Study of Afatinib with Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)
Shanthi Marur, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase I/II Study of Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed by Standard Chemoradiation in HPV Negative Locally Advanced Stage III/IVa/IVb HNSCC Patients
Lecia Sequist, MD, MPH Massachusetts General Hospital Cancer Center Randomized Phase II Study Comparing Concise (3 months) versus Prolonged (2 years) Afatinib as Adjuvant Therapy for Patients with Resected Stage I-III NSCLC with EGFR Mutation

 

Axitinib Studies

INVESTIGATOR

MEMBER INSTITUTION

STUDY
Emily Bergsland, MD/Jonathan Strosberg, MD UCSF Helen Diller Family Comprehensive Cancer Center/Moffitt Cancer Center A Phase II Study of Axitinib in Advanced Carcinoid Tumors
Alan L. Ho, MD, PhD Memorial Sloan-Kettering Cancer Center A Phase II Study of Axitinib (AG-013736) in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Nikhil I. Khushalani, MD Roswell Park Cancer Institute Predictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma
Francis P. Worden, MD University of Michigan Comprehensive Cancer Center Phase II Trial Evaluating Axitinib in Patients with Unresetable, Recurrent or Metastatic Head and Neck Cancer

 

Bendamustine Studies

INVESTIGATOR MEMBER INSTITUTION STUDY
Marc C.Chamberlain, MD University of Washington A Phase II Study of Bendamustine (Cephalon, Inc.) in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)
John C. Grecula, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy (SRT) for Patients with 1-3 Brain Metatases from Solid Malignancies
Rachel M. Layman, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Phase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Breast Cancer
Edward Pan, MD Moffitt Cancer Center Phase I Study of Bendamustine with Concurrent Whole Brain Radiation Therapy in Patients with Brain Metastases from Solid Tumors
Francisco Robert, MD/Rodolfo Bordoni, MD University of Alabama at Birmingham Comprehensive Cancer Center/Georgia Cancer Specialists Phase I/IIa Study of the Novel Combination of Bendamustine with Irinotecan Followed by Etoposide/Carboplatin in Chemonaive Patients with Extensive Stage Small Cell Lung Cancer
Apostolia-Maria Tsimberidou, MD, PhD The University of Texas MD Anderson Cancer Center A Phase I Study of Bendamustine and Bevacizumab for Patients with Advanced Cancers

 

Capecitabine Studies

INVESTIGATOR MEMBER INSTITUTION STUDY
Tanios Bekaii-Saab, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients with Advanced Pancreatic Cancer
Renuka Iyer, MD Roswell Park Cancer Institute Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer
Nikhil Khushalani, MD Roswell Park Cancer Institute Phase II Study of Capecitabine in Combination with Oxaliplatin and Radiotherapy for Esophageal and Gastroesophageal Junction Cancer
Andrew Ko, MD/Kimberly Jones, MD UCSF Helen Diller Family Comprehensive Cancer Center/Huntsman Cancer Institute at the University of Utah A Phase I Study, with expanded cohort, of Biweekly Fixed-Dose Rate Gemcitabine plus Capecitabine in Patients with Advanced Pancreatic and Biliary Carcinomas
Daniel Laheru, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Thymidylate Synthase (TS) Genotype-Directed Phase II Trial of Oral Capecitabine for 2nd Line Treatment of Advanced Pancreatic Cancer
Mary Mulcahy, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University  A Phase II Study of Capecitabine and Oxaliplatin with Radiation for Esophageal and Gastroesophageal Junction Adenocarcinoma
Lakshmi Pendyala, PhD Roswell Park Cancer Institute Gene Expression Profiling of Esophageal Cancer in Patients Receiving Oxaliplatin, Capecitabine and Radiation, Exploring Correlations to Response
M. Wasif Saif, MD, MBBS Yale University School of Medicine A Phase I/II, Open-Label, Dose Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients with Advanced Pancreatic Carcinoma
Hope Uronis, MD Duke Cancer Institute Correlative Biomarker Proposal for A Phase II Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinoma
Robert Warren, MD UCSF Helen Diller Family Comprehensive Cancer Center A Retrospective Analysis of Thymidylate Synthase (TS) and Thymidine Phosphorylase (TP) Levels and Thymidylate Synthase (TS) Genetic Polymorphisms from Archived Hepatocellular Carcinoma (HCC) Surgical Specimens

 

Celecoxib Studies

INVESTIGATOR MEMBER INSTITUTION STUDY
Manuel Hidalgo, MD, PhD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Biological Evaluation of Celecoxib in Pancreatic Cancer
Milind Javle, MD Roswell Park Cancer Institute Celecoxib in Combination with Irinotecan (CPT-11), 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer: A Phase I Study
Ritsuko Komaki, MD, FACR The University of Texas MD Anderson Cancer Center A Phase I Study of Concurrent CPT-11/Cisplatin and Celecoxib with Radiation Therapy for Patients with Unresectable Non-Small Cell Lung Cancer (NSCLC)
Nancy Lewis, MD Fox Chase Cancer Center A Randomized Trial of Celecoxib +/- Rosiglitazone vs. Placebo in Patients with Early Stage Non-Invasive Bladder Carcinoma
Brian Rini, MD UCSF Helen Diller Family Comprehensive Cancer Center A Phase II Trial of Celecoxib Plus Interferon-Alpha in Advanced Renal Cell Carcinoma
Manisha Shah, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma
Charles Shapiro, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute A Phase II Trial of Exemestane (Aromasin) in Combination with Celecoxib (Celebrex) as Neoadjuvant Treatment in Postmenopausal Women with Stage II, III, and IV Breast Cancer
Przemyslaw Twardowski, MD City of Hope Comprehensive Cancer Center Biologic Markers of Angiogenesis: A Companion Study to Phase I Trial of Oral Etoposide in Combination with Celecoxib in Patients with Advanced Malignancies and Phase I Trial of Oral Cyclophosphamide in Combination with Celecoxib in Patients with Advanced Malignancies

 

Cetuximab Studies

COORDINATING CENTER/PROJECT CHAIR PARTICIPATING MEMBER INSTITUTION/PRINCIPAL INVESTIGATOR STUDY
University of Michigan Comprehensive Cancer Center/Maha Hussain, MD, FACP City of Hope Comprehensive Cancer Center/Przemyslaw Twardowski, MD Phase II Randomized Trial of Gemcitabine and Cisplatin with or without Cetuximab in Patients with Urothelial Carcinoma
Huntsman Cancer Institute at the University of Utah/Neeraj Agarwal, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance/Evan Yu, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins/Mario Eisenberger,  MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University/Gary MacVicar, MD
Roswell Park Cancer Institute/Ellis Levine, MD
Stanford Cancer Institute/Sandy Srinivas, MD
The University of Texas MD Anderson Cancer Center/Arlene Siefker-Radtke, MD
Vanderbilt-Ingram Cancer Center/Igor Puzanov, MD
PARTICIPATING NON-MEMBER INSTITUTION/PRINCIPAL INVESTIGATOR
Boston Medical Center/Gretchen Gignac, MD
Lahey Clinic/Christopher Tretter, MD
University of Southern California/David I. Quinn, MBBS, PhD, FRACP
Wayne State University/Karmanos Cancer Institute/Ulka Vaishampayan, MD
Memorial Sloan-Kettering Cancer Center/Matthew Fury, MD, PhD City of Hope Comprehensive Cancer Center/Dean Lim, MD A Phase II Randomized Study of Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Fox Chase Cancer Center/Ranee Mehra, MD
Huntsman Cancer Institute at the University of Utah/Neeraj Agarwal, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University/Bruce Brockstein, MD
Moffitt Cancer Center/Tawee Tanvetyanon, MD
University of Tennessee Cancer Institute/Furhan Yunus, MD
UNMC Eppley Cancer Center at The Nebraska Medical Center/Sandeep Rajan, MD

 

Dabrafenib Studies

INVESTIGATOR

MEMBER INSTITUTION

STUDY
Paul Chapman, MD Memorial Sloan-Kettering Cancer Center Adjuvant Therapy of Stage IIIC BRAF-mutated Melanoma Patients with GSK2118436
Mark Kelley, MD, MMHC, FACS Vanderbilt-Ingram Cancer Center Biomarkers of Response and Resistance to Sequential B-RAF and MEK Targeted Therapy in a Pre-surgical Model of Advanced, Operable Melanoma
Martin McMahon, PhD UCSF Helen Diller Family Comprehensive Cancer Center Mechanisms of BRAF (V600E) Inhibitor Sensitivity or Resistance in Genetically Engineered Mouse Models of Malignant Melanoma
Sareh Parangi, MD Massachusetts General Hospital Acccurate Modeling of Resistance to BRAF Inhibition in an Orthotopic Animal Model of Thyroid Cancer Progression
Manisha Shah, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute A Phase I Trial of GSK2118436 (BRAFi) and Pazopanib in Patients with BRAF-mutated Advanced Malignant Solid Tumors
Manisha Shah, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute A Randomized Phase 2 Study of Single Agent GSK2118436 (BRAFi) vs Combination Regimen GSK2118436 (BRAFi) and GSK1120212 (MEKi) in Patients with BRAF Mutated Thyroid Carcinoma

 

Irinotecan Studies

INVESTIGATOR MEMBER INSTITUTION STUDY
Patrick J. Creaven, MD, PhD Roswell Park Cancer Institute Phase I Study of Irinotecan followed by Capecitabine in Patients with Advanced Breast Carcinoma
Stacy Moulder, MD Moffitt Cancer Center A Single Arm Phase II Study of Gemcitabine and Irinotecan in Patients with Metastatic Breast Cancer
Pedro Ramirez, MD The University of Texas MD Anderson Cancer Center Phase I Trial of Concurrent Weekly CPT-11, Cisplatinum, and Radiotherapy for Patients with Newly Diagnosed Stage IIIb-IVa Cancer of the Uterine Cervix
M. Wasif Saif, MD, MBBS University of Alabama at Birmingham Comprehensive Cancer Center A Phase I and Pharmacologic Trial of Sequential Administration of Bi-weekly Gemcitabine as a 24-hour IV Infusion followed by Irinotecan as a 24-hour IV Infusion in Adult Cancer Patients
Charles Shapiro, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Phase II Study of Sequentially Administered Mitomycin and Irinotecan in Patients with Refractory Metastatic and Inflammatory Breast Cancers

 

nab-Paclitaxel Studies

INVESTIGATOR MEMBER INSTITUTION STUDY
Mihaela Cristea, MD City of Hope Comprehensive Cancer Center Phase I Trial of Intraperitoneal nab-paclitaxel (Abraxane®) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity
Grace Dy, MD Roswell Park Cancer Institute SPARC Expression in NSCLC is Correlated with Response to nab-paclitaxel
Matthew G. Fury, MD, PhD Memorial Sloan-Kettering Cancer Center Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane®) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients with Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
David Hong, MD The University of Texas MD Anderson Cancer Center Phase I Trial of  Hepatic Arterial Infusion of Abraxane with a Pharmacokinetic Study in Advanced Solid Cancer Patients with Predominant Hepatic Metastases
Thomas Olencki, DO The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute A Phase 2 Study of Weekly Infusion nab-paclitaxel (paclitaxel protein-bound particles for injectable suspension) in Patients with Unresectable and Metastatic Uveal Melanoma
Gregory A. Otterson, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Phase II Trial of Abraxane plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding from VEGF Directed Therapies
Jasgit Sachdev, MD University of Tennessee Cancer Institute Neoadjuvant Weekly nab-paclitaxel (Abraxane®) Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide with Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer

 

Ofatumumab Studies

INVESTIGATOR MEMBER INSTITUTION STUDY
Seema Bhat, MD Roswell Park Cancer Institute A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia
Jennifer Brown, MD, PhD Dana-Farber Cancer Institute Ofatumumab-High Dose Methylprednisolone Followed by Ofatumumab-Alemtuzumab in 17p Deletion CLL
Alessandra Ferrajoli, MD The University of Texas MD Anderson Cancer Center Phase II Study of Ofatumumab as front-line treatment in elderly, unfit patients with Chronic Lymphocytic Leukemia (CLL)
Francisco Hernandez-Ilizaturri, MD Roswell Park Cancer Institute Ofatumumab in combination with high dose cytarabine chemoimmunotherapy for patients with newly diagnosed Mantle Cell Lymphoma (MCL)
Shuo Ma, MD, PhD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Correlative Studies in Conjunction with A Phase II Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

 

Pazopanib Studies

INVESTIGATOR MEMBER INSTITUTION STUDY
Nilofer S. Azad, MD/Ralph Zinner, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins/The University of Texas MD Anderson Cancer Center A Phase I Study Determining the Safety and Tolerability of Combination Therapy with Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK 1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched with Patients with Advanced Differentiated Thyroid Cancer
Laura QM Chow, MD University of Washington/Seattle Cancer Care Alliance A Phase I Clinical Trial of Pazopanib in Combination with Escalating Doses of Radioactive 131I in Patients with Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake
Herbert I. Hurwitz, MD Duke Cancer Institute Phase I Dose Escalation of Pazopanib Plus TH302 in Advanced Solid Tumors
Halla Nimeiri, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumor (PNET)
Manisha Shah, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute A Phase I Trial of GSK2118436 (BRAFi) and Pazopanib in Patients with BRAF-mutated Advanced Malignant Solid Tumors
William D. Tap, MD Memorial Sloan-Kettering Cancer Center A Phase IB/II Study of Gemcitabine and Docetaxel in Combination with Pazopanib (gem/doce/pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Margaret von Mehren, MD Fox Chase Cancer Center Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma
Jennifer J. Wheler, MD The University of Texas MD Anderson Cancer Center Phase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients with Advanced Solid Tumors Refractory to Standard Therapy

 

Pralatrexate Studies

INVESTIGATOR MEMBER INSTITUTION STUDY
Tanios Bekaii-Saab, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Phase II Study of Pralatrexate and Docetaxel in Patients with Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-Based Therapy
Marcela G. del Carmen, MD, MPH Massachusetts General Hospital Cancer Center Phase I/II Study of Carboplatin and Pralatrexate in Patients with Recurrent Platinum Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Jean L. Grem, MD UNMC Eppley Cancer Center at The Nebraska Medical Center A Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-Hour Infusion of 5-Fluorouracil Given Every Other Week in Adult Patients with Solid Tumors  
Alan L. Ho, MD, PhD Memorial Sloan-Kettering Cancer Center A Multi-Institution Phase II Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) 
Nihkil I. Khushalani, MD Roswell Park Cancer Institute Pralatrexate in Combination with Oxaliplatin in Advanced Esophago-Gastric Cancer: A Phase II Trial with Predictive Molecular Correlates  
Michaela Liedtke, MD Stanford Cancer Institute A Phase I Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma   

 

Sorafenib Studies

INVESTIGATOR MEMBER INSTITUTION STUDY
Ghassan K. Abou-Alfa, MD Memorial Sloan-Kettering Cancer Center Evaluation of Pre- and Post-Treatment pERK and Ask-1 as Part of a Phase II Study of Sorafenib plus Doxorubicin Combination Therapy in Patients with Advanced Hepatocellular Carcinoma with Disease Progression on Initial Sorafenib
Janet Murphy, MD, MPH Massachusetts General Hospital Correlative Biomarker Imaging with 18Fluorouracil (5-18FU) Radioisotope PET-MRI Technology in Patients Participating in a First-line Single-center FOLFOX-Sorafenib Clinical Trial in Advanced HCC
Panayiotis Savvides, MD, PhD, MPH The Ohio State University Comprehensive Cancer Center – James Cancer Hospital And Solove Research Institute Phase I/II Clinical Trial of Sorafenib in Combination with Cisplatin and Docetaxel in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Yasmin Thanavala, PhD Roswell Park Cancer Institute Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC

 

Sunitinib Studies (Preclinical)

INVESTIGATOR MEMBER INSTITUTION STUDY
Long Dang, MD, PhD University of Michigan Comprehensive Cancer Center Targeting Tumor Reactive Response to Antiangiogenic Therapy
Frank Fitzpatrick, PhD Huntsman Cancer Institute at the University of Utah Molecular Determinants of Sunitinib Efficacy
Roberto Pili, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Vertical Inhibition of the VEGF Pathway with Sunitinib in Combination with HDAC and mTOR Inhibitors in Renal Cell Carcinoma Models
Sabina Signoretti, MD and
James Mier, MD		 Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center Therapy of Renal Cell Carcinoma with Sutent: Mechanism of Acquired Resistance
John Sunwoo, MD, FACS Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine Preclinical Evaluation of Sunitinib in Squamous Cell Carcinoma of the Head and Neck
Michael Wong, MD, PhD, FRCPC Roswell Park Cancer Institute  Inhibition of Human Angiosarcoma and Reversal of Chemoresistance by Sunitinib
Sam Yoon, MD Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center Sunitinib with and without Radiation Therapy: Analysis in a Novel Mouse Model of Soft Tissue Sarcomas

 

Sunitinib Studies (Specialized Imaging)

INVESTIGATOR MEMBER INSTITUTION STUDY
John Hoffman, MD Huntsman Cancer Institute at the University of Utah Sunitinib for Metastatic Renal Cell Cancer with Imaging Biomarker Assessments for the Early Prediction of Tumor Response
Robert G. Maki, MD, PhD
 Memorial Sloan-Kettering Cancer Center 18FDG-PET As a Means to Determine Clinical Response in Soft Tissue Sarcomas in Patients Receiving a Continuous Daily Dosing Schedule of Sunitinib
Andrew Quon, MD
 Stanford Cancer Institute Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Jennifer Specht, MD Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance DCE-MRI and FDG-PET with Kinetic Analysis to Monitor Breast Cancer Response to Neoadjuvant Sunitinib and Metronomic Chemotherapy

 

Temsirolimus Studies

INVESTIGATOR MEMBER INSTITUTION STUDY
Andrew Armstrong, MD, ScM Duke Cancer Institute  Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men with Castration Resistant Metastatic Prostate Cancer
Susana M. Campos, MD, MPH Dana-Farber/ Brigham and Women's Cancer Center A Phase I/IB Study of AZD2171 (Cediranib) and Temsirolimus in Patients with Advanced Gynecological Malignancies
Sarat Chandarlapaty, MD, PhD Memorial Sloan-Kettering Cancer Center A Phase I/II Trial of Temsirolimus plus Neratinib in Patients with Metastatic HER2-Amplified or Triple- negative Breast Cancer
Warren A. Chow, MD City of Hope Comprehensive Cancer Center Randomized, Phase II Trial of AZD6244 alone and AZD6244 plus Temsirolimus for Soft Tissue Sarcomas
Ira Dunkel, MD Memorial Sloan-Kettering Cancer Center Phase I Study of Perifosine with Temsirolimus for Recurrent Pediatric Solid Tumors
Matthew G. Fury, MD, PhD Memorial Sloan-Kettering Cancer Center A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
R. Kate Kelley, MD/Halla Nimeiri, MD UCSF Helen Diller Family Comprehensive Cancer Center/Robert H. Lurie Comprehensive Cancer Center of Northwestern University A Phase I/II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
David Loeb, MD, PhD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase I/II Trial of Torisel® and Liposomal Doxorubicin in Patients with Advanced Soft Tissue and Bone Sarcomas
Eric Sherman, MD Memorial Sloan-Kettering Cancer Center Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Sandhya Srinivas, MD Stanford Cancer Institute Using Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients with Castration-Resistant Prostate Cancer
Furhan Yunus, MD, FACP University of Tennessee Cancer Institute A Phase I/II Trial of the Combination of Cisplatin, Cetuximab, and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck  

 

Tivozanib Studies

INVESTIGATOR

MEMBER INSTITUTION

STUDY
Susana Campos, MS, MD, MPH Dana-Farber/Brigham and Women's Cancer Center Platinum Sensitive Ovarian Cancer: The Use of Tivozanib as Maintenance Therapy Post Chemotherapy in Patients with Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Elizabeth Gerstner, MD Massachusetts General Hospital Cancer Center Phase II Trial of Tivozanib in Patients with Recurrent Glioblastoma
Renuka Iyer, MD Roswell Park Cancer Institute Multicenter Phase 2 Study of Tivozanib in Patients with Advanced Inoperable Hepatocellular Carcinoma
M. Dror Michaelson, MD, PhD Massachusetts General Hospital Cancer Center Phase 2 Combination Trial of Tivozanib and Enzalutamide in Men with Advanced Prostate Cancer
Julian Schink, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

 

Trametinib Studies

INVESTIGATOR

MEMBER INSTITUTION

STUDY
Adil Daud, MD UCSF Helen Diller Family Comprehensive Cancer Center Phase I/II Trial of the MEK Inhibitor GSK1120212 + PI3Kinase Inhibitor GSK 2126458 in BRAF Wild Type Melanoma (with or without NRAS mutation)
Richard Kim, MD Moffitt Cancer Center Randomized Phase II Trial of Single Agent MEK Inhibitor GSK1120212 vs 5-fluorouracil or capecitabine in refractory advanced biliary cancer
Ursula Matulonis, MD Dana-Farber/Brigham and Women's Cancer Center A Single Arm, Single Stage Phase II Open Label Trial of GSK1120212 and GSK2126458 in Persistent or Recurrent Cervical Cancer
Ravindra Uppaluri, MD, PhD Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine A Phase II Window of Opportunity Trial with GSK1120212 in Surgically Resectable Oral Squamous Cell Cancer 
Evan Wuthrick, MD The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute A Phase I Trial of MEK Inhibitor GSK1120212 in Combination with Neoadjuvant 5-Fluorouracil Chemoradiation in the Treatment of KRAS, BRAF, and NRAS-Mutant Rectal Cancers

 

Vorinostat Studies

INVESTIGATOR MEMBER INSTITUTION STUDY
Emily Chan, MD, PhD Vanderbilt-Ingram Cancer Center Phase I Trial of Chemoradiation with Capecitabine and Vorinostat in Pancreatic Cancer
Griffith Harsh, MD/Mary Pinder-Schenck, MD Stanford Cancer Institute/Moffit Cancer Center Phase I Trial of Vorinostat Concurrent with Stereotactic Radiotherapy in Treatment of Brain Metastases from Non-Small Cell Lung Cancer
Ranee Mehra, MD Fox Chase Cancer Center Phase I Study of the HDAC Inhibitor Vorinostat with Chemotherapy and Radiation Therapy for the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Theodoros N. Teknos, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute A Phase I Trial of Vorinostat in the Treatment of Advanced Oropharyngeal Carcinoma of the Head and Neck

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Quick Links




About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved